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Summary: In this review, we sought to address 2 important issues in the diagnosis of
endometrial carcinoma: how to grade endometrial endometrioid carcinomas and how
to incorporate the 4 genomic subcategories of endometrial carcinoma, as identified through
The Cancer Genome Atlas, into clinical practice. The current International Federation of
Gynecology and Obstetrics grading scheme provides prognostic information that can be used to
guide the extent of surgery and use of adjuvant chemotherapy or radiation therapy. We
recommend moving toward a binary scheme to grade endometrial endometrioid carcinomas by
considering International Federation of Gynecology and Obstetrics defined grades 1 and 2
tumors as “low grade” and grade 3 tumors as “high grade.” The current evidence base does not
support the use of a 3-tiered grading system, although this is considered standard by
International Federation of Gynecology and Obstetrics, the American College of Obstetricians
and Gynecologists, and the College of American Pathologists. As for the 4 genomic subtypes of
endometrial carcinoma (copy number low/p53 wild-type, copy number high/p53 abnormal,
polymerase E mutant, and mismatch repair deficient), which only recently have been identified,
there is accumulating evidence showing these categories can be reproducibly diagnosed and
accurately assessed based on biopsy/curettage specimens as well as hysterectomy specimens.
Furthermore, this subclassification system can be adapted for current clinical practice and is of
prognostic significance independent of conventional variables used for risk assessment in
patients with endometrial carcinoma (eg, stage). It is too soon to recommend the routine use of
genomic classification in this setting; however, with further evidence, this system may become
the basis for the subclassification of all endometrial carcinomas, supplanting (partially or
completely) histotype, and grade. These recommendations were developed from the Interna-
tional Society of Gynecological Pathologists Endometrial Carcinoma project. Key Words:
Endometrial cancer—FIGO grade—The Cancer Genome Atlas—TCGA—Genomic subtype.
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This review focuses on the grading of endometrial
endometrioid carcinoma (EEC) and the emerging
molecular classification of endometrial carcinoma. In
this review, we will discuss the pertinent literature and
make recommendations as appropriate. At the end of
each section, we will identify unresolved issues for
which there are currently insufficient data to make
recommendations, with the hope that these issues will
be investigated in future research. These recommen-
dations were developed by the authors as part of the
International Society of Gynecologic Pathologists
Endometrial Carcinoma Project.
TOPIC 1: HOWTOAPPLY THE INTERNATIONAL
FEDERATION OF GYNECOLOGY
AND OBSTETRICS (FIGO) GRADING SYSTEM
FOR EEC
According to current practice standards, EECs are
assigned a FIGO grade based on the degree of glandular
differentiation. Grade 1 tumors exhibit ≤5% solid
nonglandular, nonsquamous growth; grade 2 tumors
from 6% to 50%; and grade 3 tumors >50% (1–3). The
presence of marked cytologic atypia increases the grade 1
level. Since mucinous adenocarcinomas of the endome-
trium are closely related to endometrioid carcinomas, it
is reasonable to use FIGO grade for those carcinomas as
well. However, FIGO grading should NOT be used
when endometrioid or mucinous differentiation is in
doubt or cannot be established. All of the other
endometrial tumor types carry an intrinsic tumor grade
(i.e. serous, clear cell, and undifferentiated carcinomas
and carcinosarcomas are high grade). Strategies for
grading mixed epithelial tumors will be discussed later in
this review and in another review in this issue.
In clinical practice, determining FIGO grade is not
always clear-cut. On the basis of personal experience
and anecdotes accrued during participation in the
Gynecologic Oncologic Group Pathology section, it
appears that many pathologists consider tight, small
microacini with barely visible lumens as solid growth,
although FIGO grading rules do not specifically
discuss this and some pathologists characterize such
patterns as “glandular” (Fig. 1). For the purposes of
grading, we endorse that a confluent microacinar pattern
constitutes “solid” growth, although this is not evidence
based. As stated in the FIGO criteria, squamous
differentiation should be discounted as evidence of solid
growth, but there are inevitable problems with grading
tumors containing solid growth that resembles immature
squamous epithelium and tumors that feature transitions
between nonkeratinizing squamous epithelium and
spindle cell change. It is reasonable to adjudicate these
types of cases by paying attention to the nuclear grade,
first in the glandular component and then, if that
approach is not informative, in the solid component.
We designate a tumor as FIGO grade 3 if the solid areas
resemble poorly differentiated nonkeratinizing squamous
cell carcinoma.
Another common problem in grading concerns the
degree and extent of nuclear atypia that is sufficient to
upgrade a tumor from 1 FIGO category to another
(4,5). The philosophy underlying our approach to this
problem is that discordance between architectural
grade and nuclear grade should be uncommon in
endometrioid adenocarcinomas. The first step is to
ensure the nuclear features are sufficiently atypical.
An easy guideline is to ask yourself, “Is this focus
easily appreciated on scanning or intermediate power
examination?” and “Is the atypia so bad that I would
consider it grade 3 on a 3-point scale?” If the answers
are “yes,” you should sample the tumor extensively to
determine whether the finding is limited only to a few
glands. If the change is diffuse, it is advisable to at least
question whether part or all of the tumor could be a
serous carcinoma or a clear cell carcinoma, instead of
an endometrioid carcinoma (6). It is acceptable to move
such a tumor from 1 FIGO grade to another only after
determining that the tumor is indeed endometrioid
throughout. A mixed epithelial carcinoma with an
endometrioid component should be diagnosed when the
cytologically atypical area is determined to be serous or
clear cell on further study. One should not upgrade
endometrioid carcinomas containing only a few glands
with atypical nuclei, especially if it took a prolonged
search at high-power magnification to recognize them.
We endorse the severe nuclear atypia qualification
described by Zaino et al. (4), that is, that severe nuclear
atypia in the majority of cells (> 50%) is required to
upgrade a grade 1 or 2 EEC. “Upgrading” a case based
on nuclear features is only rarely prudent, as in most
cases, tumors are upgraded inappropriately (nuclear
atypia is mild-moderate and diffuse, or severe and only
focally found) or are not endometrioid at all.
Classification and regression tree statistical analyses
have demonstrated that after tumor stage, the next most
informative prognostic division in EEC is between high-
grade (grade 3) and low-grade (grade 1/2) tumors (7,8).
Although it is reported that there is a small but
statistically significant difference in survival of up to 5%
between clinically low-stage grades 1 and 2 EECs (9),
this has not been consistently demonstrated. Therefore,
the key consideration in tumor grading at hysterectomy
should be to identify the presence of grade 3 EEC or
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any other high-grade components that may adversely
affect patient prognosis, and not in trying to distinguish
between grades 1 and 2 EEC. We have designated this
system as “binary FIGO,” which entails combining
grades 1 and 2 tumors into a low-grade category and
grade 3 tumors into a high-grade category (10,11). Said
another way, EECs with low nuclear grade and
harboring ≤50% solid tumor components would be
considered “low-grade EEC” (Fig. 1). This is in keeping
with current risk assessment/treatment guidelines, such
as those of the National Comprehensive Cancer
Network (NCCN), European Society of Medical
Oncology (12), the Mayo Clinic (13), and Memorial
Sloan Kettering Cancer Center (MSK) in which grades
1 and 2 EECs are managed the same way. Although
NCCN (NCCN guideline version 1.2018) still
recognizes 3 EEC grades, the staging and therapeutic
guidelines for grades 1 and 2 are very similar. Differences
in the risk of lymph node metastasis in grades 1 and 2
EEC are most pronounced when decisions for staging
are undertaken by evaluating biopsy or curettage
material only. As will be discussed subsequently, the
distinction between grades 1 and 2 is unimportant in the
setting of planned lymphadenectomy or sentinel lymph
node mapping, and distinguishing between these grades
does not stratify patients who have had comprehensive
surgical staging into different risk categories.
A literature review of various proposed binary
grading schemes (summarized in Table 1 and a recent
review on grading EEC) (1) reveals that EECs can
readily be divided into either a low-risk or high-risk
prognostic group based on a number of factors
FIG. 1. Examples of low-grade and high-grade endometrial endometrioid carcinomas (EEC): (A) low-grade EEC [International Federation of
Gynecology and Obstetrics (FIGO) grade 1) with extensive squamous differentiation that does not qualify as “solid” for the purposes of
grading; (B) low-grade EEC (FIGO grade 2) with <50% solid nonsquamous growth; (C) low-grade EEC (FIGO grade 2) with <50% solid
nonsquamous growth; and (D) high-grade EEC with a microacinar growth pattern that qualifies as “solid growth.” The presence of microacini
should not be considered “glandular” for the purposes of assigning binary or FIGO grade.
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associated with increased tumor aggressiveness; the
different grading systems show only slight disagreement
over the distribution of a small number of gray-area
cases between the 2 main prognostic groups. All of the
proposed 2-tiered grading systems have been shown to
be equal or superior to the current 3-tiered FIGO
system in terms of interobserver variability kappa score,
and the binary FIGO system, in the studies in which it
was assessed, consistently exceeded the 3-tiered FIGO
system. The binary FIGO system also performs as well
as or better in terms of prognostication, compared with
other binary grading schemes, and has the added
advantage of being based on the currently used FIGO
grading system (i.e. practicing pathologists are already
familiar with the system’s criteria). An assessment of the
potential clinical impact of the adoption of a binary
EEC grading system is complicated by variations in
clinical patient management, as well as the absence of a
widely accepted consensus on the indications for
extensive surgical staging in patients with a
preoperative diagnosis of low-grade EEC. Soslow and
colleagues recently analyzed a departmental database of
clinical stage 1 EECs (n= 1544) to better understand
relationships between preoperative tumor grade, depth
of myometrial invasion, and the risk of positive sentinel
lymph nodes. The analysis demonstrated that while
grade 1 tumors were associated with a significantly
lower rate of lymph node metastases compared with
grade 2 tumors overall (6.6% vs. 11.6%; P= 0.003), the
difference disappeared after adjusting for depth of
myometrial invasion (Table 2) (1). Those findings
further endorse the view that preoperative tumor
grade alone should not be used to assess the
indication for extensive surgical staging. The use of
preoperative tumor grade alone to select patients for
lymphadenectomy is clearly not supported by the
evidence and does not reflect the complex interplay
between the various pathologic parameters. In
summary, we propose that it would be appropriate to
adopt a binary FIGO system for grading EEC by
combining the grades 1 and 2 categories into a single
low-grade category in biopsy or curettages when
comprehensive surgical staging is planned and in
hysterectomy specimens. For patients desiring a
fertility-sparing therapeutic approach, it will continue
to be necessary to distinguish grades 1 and 2 based on
currently used clinical criteria for conservative,
hormonal therapy whereby grade 1 tumors can be
considered for this approach and grade 2 tumors will
generally not (NCCN guideline version 1.2018). We
also propose to retain the severe nuclear atypia
qualification, based on the work of Zaino et al. (4),
whereby severe nuclear atypia in the majority of cells
(>50%) in an architecturally low-grade EEC would
lead to a high-grade designation. This proposed system
should be beneficial in terms of simplification and
diagnostic reproducibility.
RECOMMENDATIONS
 Discuss individual clinician’s preferences for mov-
ing to a binary grading scheme, while emphasizing
its potential benefits.
 As a bridge toward uniform adoption of the binary
FIGO grading scheme, it is acceptable to report
both the binary grade and the FIGO grade [i.e.
low-grade EEC (FIGO grade 2)].
 Going forward, we recommend the adoption of the
binary FIGO grading system, when appropriate.
Existing reporting data sets/synoptic templates/
TABLE 1. Interobserver and intraobserver variability









Binary FIGO (10,11) 0.58–0.71 0.9
Lax et al (10,11,14) 0.39–0.75 0.67–0.79
Taylor et al (15) 0.90 (biopsy); 0.97
(hysterectomy)
Alkushi et al (10) 0.76 0.81
*Kappa statistics.
FIGO indicates International Federation of Gynecology and
Obstetrics.
TABLE 2. Rate of lymph node metastases in clinical stage 1
endometrial carcinoma in terms of preoperative tumor grade
and depth of myometrial invasion (DMI) on hysterectomy:
apparent differences in nodal positivity rates between grades




























29/95 (30.5) 28/101 (27.7) 0.75 23/70 (32.9)
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checklists for reporting endometrial carcinoma will
need to be revised and updated.
UNRESOLVED ISSUES
Anticipating the future incorporation of The
Cancer Genome Atlas (TCGA) classification system
into endometrial cancer diagnosis and prognostica-
tion, it remains uncertain whether grading will remain
an important clinical discriminator for tumors,
especially in the polymerase E (POLE) category.
TOPIC 2: HOW TO SYNTHESIZE
GENOMICALLY DEFINED TYPES OF
ENDOMETRIAL CARCINOMA WITH THEIR
MORPHOLOGIC, IMMUNOPHENOTYPIC,
AND CLINICAL CHARACTERISTICS
For the purposes of this review, FIGO grade 3
endometrioid, serous, and clear cell carcinomas will
be considered “high-grade endometrial carcinomas”
(HGECs). Undifferentiated and dedifferentiated car-
cinomas and carcinosarcomas are dealt with else-
where in this review series.
Various studies have shown that an HGEC
diagnosis is not highly reproducible (21,22). This
implies that: (1) diagnostic criteria are insufficiently
detailed for practical use; (2) and/or diagnostic criteria
were developed empirically and may not be evidence
based; (3) and/or uniform diagnostic criteria are not
utilized in practice. This lack of reproducibility is
significant in that the reported clinicopathologic and
molecular data concerning HGEC may not be readily
interpreted because of differences in case series based
on inconsistent diagnoses. Examples of the latter
problem are the lack of consensus regarding whether
grade 3 endometrioid carcinomas are “type II
endometrial carcinomas” and whether they are as
aggressive as serous carcinomas.
There have been a number of attempts to refine
diagnostic criteria using evidence-based approaches.
Among other groups, the MSK group used immuno-
histochemical and clinical evidence to describe gland-
forming serous carcinomas that are distinct from
FIGO grades 1 and 2 endometrioid carcinomas (4,23)
(Fig. 2); the MD Anderson group used supporting
clinical evidence to separate undifferentiated
carcinomas from grade 3 endometrioid carcinomas;
(24,25) the Massachusetts General Hospital group
used supporting clinical evidence to separate corded
and hyalinized endometrioid carcinomas from
carcinosarcomas; (26) and the Vancouver group used
a genomically based classifier to refine diagnostic criteria
that more precisely separate grade 3 endometrioid
carcinoma with a papillary/villoglandular or solid
architectural pattern from serous carcinomas with
similar architecture (27). These latter criteria also
have clinical relevance.
Publication of the TCGA endometrial carcinoma
data set has provided pathologists a unique oppor-
tunity to further refine diagnostic criteria for serous
and grade 3 endometrioid carcinomas (28). These data
do not include information about clear cell carcino-
ma, undifferentiated/dedifferentiated carcinoma, or
carcinosarcoma.
Unlike the Bokhman “type I versus type II”
classification of endometrial carcinoma, TCGA data
indicated 4 genomic types of endometrial carcinoma.
These subcategories of endometrial carcinoma were
identified based on their genomic architecture. They
include the following: POLE mutated/ultramutated;
microsatellite instability-high (MSI-H)/hypermutated;
copy number low (conceptually similar to “type I”
endometrial carcinoma); and copy number high
(presence of many genomic amplifications and/or
deletions), also known as “the serous-like group,”
which is similar to “type II” endometrial carcinoma.
The copy number low group has the lowest mutation
burden, whereas the hypermutated and ultramutated
FIG. 2. Serous carcinoma with a glandular pattern. Serous differ-
entiation can be recognized at intermediate-power magnification by
the presence of cells with high nuclear-to-cytoplasmic ratios and at
high power by the presence of enlarged and atypical nuclei.
Confirmatory endometrioid features are lacking. The diagnosis
can be confirmed with a p53 immunohistochemical stain, which
shows mutation-type staining in at least 90% of serous carcinomas.
Although mutation-type p53 staining can be present in endome-
trioid carcinomas, almost all are International Federation of
Gynecology and Obstetrics grade 3 carcinomas, which glandular
serous carcinomas do not resemble.
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groups have, on average, 10-fold and 100-fold more
mutations, respectively; the higher mutation burdens
in these latter 2 groups are secondary to defects in
mismatch repair (MMR) and POLE-mediated DNA
repair, respectively. Note that mutations in TP53 were
a distinguishing feature, when comparing copy
number high versus copy number low groups
(Fig. 3), once POLE and MSI tumors were excluded.
The overwhelming majority of low-grade (FIGO
grades 1 and 2) endometrioid carcinomas map to the
copy number low and MSI-H categories. Grade 3
endometrioid carcinomas are highly heterogenous, as
they are found in every genomic category, and are
least represented in the copy number low group.
Endometrioid carcinomas mostly have an endometrioid
genomic profile, with or without TP53 mutation/high
copy number alterations, whereas serous carcinomas have
TP53 mutations/high copy number alterations without
additional mutations characteristic of endometrioid
carcinomas.
Assigning a tumor to the serous category requires the
presence of a TP53 mutation/abnormal “mutation
pattern” p53 immunostaining, the absence of endome-
trioid-type mutations (although this point is debatable,
as some low-grade endometrioid carcinomas with
PTEN mutations acquire TP53 mutations during
tumor progression, along with “serous” morphology),
and the presence of high copy number alterations. All
serous carcinomas map to the copy number high,
“serous-like” category, as do approximately one quarter
of grade 3 endometrioid carcinomas. Although TCGA
data are incomplete, they were sufficient to generate a
Kaplan-Meier survival curve showing that POLE
carcinomas have outstanding clinical outcomes irre-
spective of grade and perhaps stage. MSI-H and copy
number low tumors have intermediate clinical risk, and
the serous-like group, unsurprisingly, has the worst
outcomes.
The first approach to extracting this information for
practical diagnostic use was to describe the morphology
of endometrioid carcinomas in each group. Although
there are many characteristic features of tumors from the
POLE (29,30) (peritumoral lymphocytes, tumor infiltrat-
ing lymphocytes, and intratumoral heterogeneity, tumor
giant cells), MSI-H (31,32) (peritumoral lymphocytes,
tumor infiltrating lymphocytes, and intratumoral hetero-
geneity), and serous-like groups (diffuse high nuclear
grade), there is a general feeling that these features are
incomplete, partly overlapping, and may not be able to
be applied reproducibly. A particular problem that is not
adequately addressed with a morphology-only approach
is the existence of morphologically ambiguous tumors
that reside in the POLE, MSI-H, and serous-like
categories (but not the copy number low category)
(33), and many POLE endometrioid carcinomas have
components or subclones that are histologically similar
to serous carcinomas. Given the particular heterogeneity
of grade 3 endometrioid carcinomas, we were faced with
the following questions and answers:
 Are serous-like grade 3 endometrioid carcinomas,
as genetically defined, really endometrioid based on
morphologic features/light microscopic examina-
tion?
○ In some cases, they can show unequivocally
endometrioid morphologic features, for example,
squamous differentiation (34). Many are histologi-
cally ambiguous, as mentioned above, making the
distinction between serous-like grade 3 endome-
trioid and serous carcinomas difficult or impossible;
this also raises the question of whether there is a
justification for attempting to separate these tumors.
 Are serous-like grade 3 endometrioid carcinomas
clinically interchangeable with serous carcinomas?
○ TP53-mutated grade 3 endometrioid carcinomas,
compared with those lacking TP53mutation, recur
more frequently (T. Bosse et al., Am J Surg Pathol
2018, in press) (35). Detailed analyses indicate that
TP53-mutated grade 3 endometrioid carcinomas
(i.e. serous-like grade 3 endometrioid carcinomas)
have a high-risk profile, with only rare exceptions.
Although there are few such cases, it appears that
TP53-mutated grade 3 endometrioid carcinomas
from the POLE category retain the clinically low-
risk profile of POLE endometrioid carcinomas that
FIG. 3. The Cancer Genome Atlas (TCGA) mutational data
arranged by genomic clusters. Data from TCGA showing that TP53
mutation analysis is a sensitive and specific method for distinguish-
ing between copy number high and copy number low tumors. Note,
however, that TP53 mutations are also seen in polymerase E
(POLE) and microsatellite instability-high (MSI-H) tumors.
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lack a TP53 mutation. There are sparse data
suggesting that serous-like grade 3 endometrioid
carcinomas metastasize to the peritoneum less
frequently than serous carcinomas, but this
requires validation. Currently, there is no compel-
ling evidence to support that serous-like grade 3
endometrioid carcinomas are significantly clinically
different than serous carcinomas, and unless there
is improvement in diagnostic reproducibility for
these 2 categories, it is difficult to envision such a
distinction being a variable that can be used to
guide patient treatment decisions.
 Can p53 immunohistochemistry alone be used to
identify those grade 3 endometrioid carcinomas
that belong to the copy number high group?
○ No. As aberrant p53 staining is not confined to
tumors in the serous-like category, additional
ancillary tests would be necessary to exclude a
TP53-mutated POLE or MSI-H grade 3 endome-
trioid carcinoma. Of interest, many TP53 muta-
tions found in the POLE and MSI-H categories
involve portions of the TP53 gene that are not
mutated in serous carcinomas (36), leading to
imperfect correlation between TP53 mutation and
aberrant p53 staining in these groups of tumors.
 Is there a better assay than p53 immunohistochem-
istry to determine which grade 3 endometrioid
carcinomas are serous-like?
○ p53 immunohistochemistry was compared with
TP53 mutational analysis and fluorescent in situ
hybridization for copy number analysis and found
to be equivalent in identifying the copy number
high serous/serous-like group (36) (see below).
Since aberrant p53 immunostaining is not synon-
ymous with a copy number high tumor, other
methods may prove to be superior surrogate
markers of this genomic subtype. Aneuploidy,
which is intuitively a good candidate marker of
copy number high tumor, frequently was found to
be present within the MSI-H and POLE categories,
so testing to exclude MSI-H and POLE is, at this
time, necessary before separation of copy number
high and low tumors (37).
We used TCGA data to extract surrogate markers for
the genome-wide analyses used to classify endometrial
cancers into 1 of the 4 genomic categories, and then
validated the classifier in an independent set of cases; this
classifier, referred to as the ProMisE (Proactive Molecular
Risk Classifier for Endometrial Cancer) classifier, includes
MMR immunostaining (rather than MSI analysis, as was
used in TCGA), sequencing of POLE exonuclease
domains (rather than quantification of mutations genome
wide) and p53 immunohistochemistry (rather than
quantification of copy number alterations genome wide
or TP53mutational analysis), and was able to recreate the
4 prognostically significant genomic subsets of endome-
trial carcinoma (36,38) (Table 3). An identical strategy
independently used by the group from Leiden was applied
to clinical trial cases and also demonstrated that the 4
molecular subtypes are of prognostic significance (39).
Proposal
On the basis of this information, we propose a
multimodality classification system of HGECs that
separates the 4 genomically defined groups of HGEC
using only the following assays (Table 3 and Fig. 4):
POLE mutational analysis and immunohistochemistry







Ultramutated POLE mutation None available
Hypermutated MSI-H MMR-D
Copy number high TP53 mutation p53 abn




abn indicates abnormal; IHC, immunohistochemistry; MMR-D,
mismatch repair deficient; MSI-H, microsatellite instability-high;
POLE, polymerase E; wt, wild-type.
FIG. 4. Harnessing The Cancer Genome Atlas (TCGA) data for
clinical diagnosis. CN-H indicates copy number high (serous or
serous-like endometrial carcinoma); CN-L, copy number low (type I
EMC); EMC, endometrial carcinoma; MSI-H, microsatellite
instability-high; POLE, polymerase E hotspot mutant tumor.
EMC*: This may also be applicable to clear cell carcinomas. Most
cases can be separated with review of hematoxylin and eosin slides.
EMC**: This assay does not distinguish CN-H grade 3 endome-
trioid carcinoma or CN-H clear cell carcinoma from serous
carcinoma.
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for p53 and the DNA MMR markers PMS2 and
MSH6. As noted previously, this algorithm has been
validated in 3 independent case series, including in Post
Operative Radiation Therapy in Endometrial Carcinoma
(PORTEC) clinical trial cases (36,38,39).
This multimodality molecular classification system
may not be feasible in many pathology laboratories,
especially in resource-restricted areas of the world. In
resource-rich regions of the world, the main impedi-
ment to making this proposal the standard of care is
not only buy-in from our clinical colleagues and the
availability of POLE mutational testing, but also the
recognition by regulatory authorities that this is a
crucial, medically valid, and necessary assay (and in
the United States, this means being worthy of
reimbursement by insurance companies).
For laboratories that do not have the means to
perform POLE mutational analysis, it will still be
possible to identify the MMR-deficient (MMR-D) and
p53 abnormal groups using immunostaining with a
3-marker panel (PMS2, MSH6, and p53). The ∼8% of
endometrial cancers in the POLE group will not be
identified, and separating these frequently histologically
high-grade and FIGO stage I carcinomas from serous
carcinomas will remain a problem. At this time, we do
not know if the favorable prognosis of the histologically
high-grade POLE-mutant endometrial cancers reflects
indolent biology, effective most immunity, or a good
response to treatment, and until this is resolved through
clinical trials, conventional therapy, based on current risk
assessment (eg, European Society of Medical Oncology
guidelines), will continue to be implemented for these
tumors, and their prognosis will remain excellent.
There is also some resistance to performing
universal DNA MMR protein immunohistochemis-
try. The clinical argument for universal MMR testing
is compelling, and this approach is recommended in
the NCCN guidelines (NCCN guideline version
1.2018) for Lynch syndrome triage and in another
review in this issue. There are other benefits to
universal testing, as it may be used as an ancillary
diagnostic test (i.e. to help exclude a serous carcinoma
or to help assign endometrial rather than cervical
primary site) and, in the setting of recurrent endo-
metrial carcinoma, it provides therapeutic prediction
for the use of immunotherapy.
What about clear cell carcinomas? Work from the
MSK group indicates that endometrial clear cell
carcinomas are just as heterogenous as grade 3
endometrioid carcinomas. There are POLE hotspot
mutated, MSI-H, copy number low, and copy number
high (serous-like) clear cell carcinomas, and those in
the copy number low and serous-like clusters have
significantly worse clinical outcomes compared with
the others (40). Once this work is confirmed by other
groups, we would provisionally propose that clear cell
carcinomas be classified based on the same multi-
modality system as that of grade 3 endometrioid
carcinomas.
Related and Unresolved Issues
Terminology
Current treatment paradigms rely on the classic
parameters of tumor histotype, especially the distinction
between endometrioid versus nonendometrioid histology,
and grade (i.e. FIGO grade as applied to endometrioid-
type tumors). Therefore, any recommended terminology
using the genomic classifier must continue to clearly
include these parameters for the foreseeable future,
although unpublished data from MSK and recently
published data from Vancouver (36,38) indicate that
prognosis is independent of histotype (in a multivariate
model), and instead depends on stage, grade, and
genomic classification. We would therefore recommend
that reporting the genomic classifier be clearly noted, as
well as the analyses used to assign the classification. For
example:
Endometrioid endometrial carcinoma, FIGO grade
3. Genomic classifier group: Copy number high (p53
abnormal by immunostaining)
Or
Mixed endometrioid and serous carcinoma. Genomic
classifier group: POLE (POLE exonuclease mutation
identified by sequencing)
When to Utilize the ProMisE Algorithm
Universal MMR testing should be performed on
biopsy/curettage material in patients desiring fertility-
sparing conservative medical management, since the
recognition of Lynch syndrome in such cases would
encourage prophylactic hysterectomy and bilateral
salpingo-oophorectomy at the appropriate age. These
tests should also be considered in biopsy/curettage
material when treatment planning depends on
genomic classification. This is not yet a standard
practice, although selected gynecologic pathology
teams are currently using this approach. It should
also be noted that antigen preservation may be
superior in biopsies/curettages compared with
hysterectomy specimens, and that molecular classi-
fication based on the biopsy does accurately reflect the
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findings in the subsequent hysterectomy specimen
(41,42).
Tumor Grading
Tumor grading in the context of molecular subtype is
a complex issue. FIGO grading is presumably only
appropriate for tumors that are within the MSI-H/
MMR-D or copy number low (also referred to as
tumors with no specific molecular profile, as they lack
POLE mutation, MMR deficiency, or abnormal p53
immunostaining) groups, as these most clearly corre-
spond to the “classic” endometrioid tumors. FIGO
grading in these 2 groups may provide the prognostic
information that one expects from older, histology-
based clinical studies, and would allow them to be
provisionally placed into low-risk and high-risk groups,
although this remains to be studied. In contrast, tumors
in the copy number high/p53 abnormal group (serous-
like) clearly belong in the “high-risk” group, in which
no histologic grading is appropriate. There is likely no
value in assigning grade to tumors in the POLE group,
for which studies indicate a survival rate approaching
100%. A significant proportion of these tumors
morphologically would be considered high grade and
could potentially be treated with unnecessary lympha-
denectomy and chemotherapy. The intersection of
genomic classification, surgical staging, and delivery
of adjuvant therapy is not yet resolved.
Intratumoral Heterogeneity
Some researchers strongly believe that endometrial
carcinomas are more heterogenous than their ovarian
counterparts (i.e. more likely to contain true mixed
tumors). Van Esterik et al. (43) demonstrated that this
morphologic heterogeneity does not extend to the
level of genomic abnormalities, that is, genomic
subtype is uniform throughout.
Many tumors assigned to the MMR-D/MSI-H and
POLE categories demonstrate significant intratumoral
morphologic heterogeneity, whereas tumors in these
groups and the p53 abnormal/copy number high cluster
also typically show morphologic ambiguity (44,45) that
gives rise to diagnostic problems (33). Hence, where does
intratumoral heterogeneity stop and mixed epithelial
carcinoma begin? Given emerging data (46) indicating
that most mixed epithelial carcinomas represent different
morphologic expressions of 1 clonal tumor, one is left
with the impression that mixed epithelial carcinomas
may not be diagnosed with any frequency in the future,
apart from some exceptional situations, for example,
grade 1 EEC giving rise to undifferentiated carcinoma.
Also, what do we make of the assertion that any type II
component of a mixed epithelial carcinoma places the
tumor in a clinically high-risk category? It is probable
that most “mixed epithelial carcinomas” with poor
clinical outcomes represent heterogenous or morpholog-
ically ambiguous p53 abnormal/copy number high
tumors. Other examples, however, likely represent
heterogenous or ambiguous POLE or MSI-H tumors
whose clinical behavior is baseline or favorable despite
the histologically high-grade appearance of 1 portion of
the tumor. These concepts need to be developed further
and validated with good clinical, morphologic, and
genomic data. For the time being, it is reasonable to
continue to follow the ISGP recommendation that
grading mixed epithelial carcinomas (such as mixed
endometrioid and serous or clear cell carcinoma) be
based on the highest grade component (discussed in
another review in this issue). However, it also must be
recognized this practice may not be clinically informative
in MSI-H and POLE tumors.
SUMMARY/RECOMMENDATIONS
 TCGA classification separates prognostically favor-
able from unfavorable types of FIGO grade 3
endometrioid carcinoma. Furthermore, it separates
serous carcinoma from hitherto unknown types of
clinically low-grade endometrial carcinomas that can
morphologically mimic serous carcinoma to a sub-
stantial degree (eg, POLE, MMR-D). The classifica-
tion is powerfully prognostically relevant and is
independently associated with clinical outcomes,
unlike histologic subtype assignment based on exami-
nation of hematoxylin and eosin slides alone.
 In laboratories undertaking genomic classification,
this should be reported in conjunction with grade
and histotype.
UNRESOLVED ISSUES
 Since the practical application of TCGA classifica-
tion relies on universal POLE gene sequencing and
universal immunohistochemistry for p53 and 2 or 4
of the DNA MMR markers, reimbursement and
financial issues need to be considered. We do not
expect significant problems with implementation
once regulatory authorities understand the poten-
tially enormous clinical impact of these assays.
 Once regulatory and financial issues are resolved,
the most efficient workflow for accomplishing the
ancillary tests, interpreting them and incorporating
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them into a diagnostic report that synthesizes
morphology, POLE genotype and immunopheno-
type will need to be defined.
 As accumulating data already suggest modifica-
tions to the “high-intermediate risk category” of
uterus-confined endometrial carcinoma based on
ProMisE/TCGA cluster assignment, clinical trials
to validate its usefulness for clinical applications
will be needed.
 It is uncertain whether it will continue to be
necessary to distinguish serous-like (p53 abnor-
mal/copy number high) FIGO grade 3 endome-
trioid, serous, and clear cell carcinomas.
 Although there are data indicating that the
ProMisE classifier reliably assigns matched tumors
from preoperative and hysterectomy specimens to
the same genomic group (40,41), it is uncertain
whether preoperative ProMisE/TCGA classifica-
tion (using biopsy or curettage material) can be
used to triage patients to different types of staging
surgery. For example, patients with POLE-mutant
tumors might not need comprehensive surgical
staging. Similarly, patients with serous and serous-
like carcinomas may not benefit from comprehen-
sive surgical staging, since nearly all will require
adjuvant chemotherapy, and it is possible that
comprehensive surgical staging may only be
applicable to the remaining categories.
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